{
  "id": 655206,
  "title": "BD completes enrollment in hernia prevention mesh trial",
  "url": "https://urgent.news/2026/08/12/bd-completes-enrollment-in-hernia-prevention-mesh-trial",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-12T10:56:29.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/bd-completes-enrollment-in-hernia-prevention-mesh-trial-93CH-4854367"
  },
  "original_language": "en",
  "account": "Franklin Lakes, N.J. - BD (NYSE:BDX) has announced the completion of enrollment for its PREVENT clinical trial assessing Phasix Mesh as a method to prevent incisional hernias post-abdominal surgery. The study, involving 477 participants across 32 locations in the U.S. and Europe, is the initial extensive randomized trial exploring preventive reinforcement for incisional hernia development using a resorbable mesh. Currently, there are no approved products for this purpose. The trial aims to determine the efficacy of Phasix Mesh in preventing incisional hernias after elective open midline abdominal surgery in patients deemed high-risk for hernia formation. Rian Seger, BD's worldwide president of Surgery, highlighted that the trial underscores the company's commitment to expanding the use of tissue regeneration technologies in new areas of patient care. Patients will be monitored until the 24-month primary endpoint, with extended follow-ups planned up to five years to examine safety and clinical outcomes. Subsequent to the primary endpoint assessments, BD intends to utilize the gathered data to support a potential FDA submission for this indication. BD is a globally operating medical technology company with over 60,000 employees, offering products and services in medical essentials, connected care, biopharma systems, and interventional categories. This report was AI-assisted and reviewed by an editor for accuracy.",
  "summary": null,
  "key_points": [
    "BD completes PREVENT trial enrollment for Phasix Mesh.",
    "477 participants across 32 sites in U.S. and Europe.",
    "Trial assesses mesh efficacy in preventing incisional hernias."
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}